KIT and systemic mastocytosis: LADR and LAD2 cells do not harbor mutations in KIT, expressed by as much as 80% of patients with systemic mastocytosis (SM), representing a disadvantage of this cell line for studying emerging therapeutics directed at KIT D816V.